Insider Trading Tracker: Live US Stock Disclosures & Insider Buying made on Jan 31, 2025

Advanced/Help

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Showing you 400 results sorted by most recent dates. Subscribe to see a larger data set

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
XBiotech Inc	John Simard	Director, Chief Executive Officer, Ten Percent Owner	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	2,470,355	870,381	-		-	Convertible Loan Agreement
Silgan Holdings Inc	R. Philip Silver	See Remarks below.	Gift of securities by or to the insider at price $ 0.00 per share.	31 Jan 2025	2,100,000	10,044,274 (9%)	1%		0	Common Stock
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	1,948,957	1,948,958	-		0	Class A Common Stock
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Director, President and CEO	Sale or transfer of securities back to the company at price $ 0.00 per share.	31 Jan 2025	1,300,000	0	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	1,300,000	1,300,000	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Ten Percent Owner	Sale or transfer of securities back to the company at price $ 0.00 per share.	31 Jan 2025	1,300,000	0	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	1,300,000	1,300,000	-		-	Stock Options
Heron Therapeutics Inc	Craig A. Collard	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	1,113,240	1,113,240	-		-	Employee Stock Option (Right to Buy)
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	1,080,617	1,080,617	-		0	Class A Common Stock
Akebia Therapeutics Inc	John P. Butler	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	1,051,400	1,051,400	-		-	Stock Option (Right to buy)
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	903,796	903,795	-		0	Class A Common Stock
Xeris Biopharma Holdings Inc	John P. Shannon	Director, See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	800,000	2,687,118 (9%)	2%		0	Common Stock
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	778,628	778,627	-		0	Class A Common Stock
Adicet Bio Inc	Chen Schor	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	763,829	763,829	-		-	Stock Option (Right to Buy)
Adicet Bio Inc	Julia D. Maltzman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	750,000	750,000	-		-	Stock Option (Right to Buy)
Beta Bionics Inc	Sean Saint	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	749,445	749,445	-		-	Employee Stock Option (right to buy)
Akebia Therapeutics Inc	John P. Butler	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	701,000	2,748,580 (2%)	0%		0	Common Stock
Kosmos Energy Ltd	Andrew G. Inglis	Director, Chairman and CEO		31 Jan 2025	691,976	4,339,392 (1%)	0%		0	Common Stock
Karyopharm Therapeutics Inc	Lori Macomber	EVP, CFO & Treasurer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	650,000	650,000	-		-	Stock Option (right to buy)
Cognition Therapeutics Inc	Lisa Ricciardi	Director, CEO & President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	631,300	893,685	-		0	Common Stock
Xeris Biopharma Holdings Inc	John P. Shannon	Director, See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	600,000	600,000	-		-	Stock Appreciation Right
Heron Therapeutics Inc	Craig A. Collard	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	556,620	556,620	-		-	Restricted Stock Units
Xeris Biopharma Holdings Inc	Kevin McCulloch	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	500,000	500,000	-		-	Stock Appreciation Right
Beta Bionics Inc	Sean Saint	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	494,198	494,198	-		-	Employee Stock Option (right to buy)
Kinder Morgan (Class P) Results Board Meeting	John W. Schlosser	V.P. (President, Terminals)	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	480,498	483,717 (0%)	0%		0	Class P Common Stock
Kinder Morgan (Class P) Results Board Meeting	John W. Schlosser	V.P. (President, Terminals)	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	480,498	0	-		-	Restricted Stock Unit
Beta Bionics Inc	Sean Saint	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	467,944	467,944	-		-	Employee Stock Option (right to buy)
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Director, President and CEO	Sale or transfer of securities back to the company at price $ 0.00 per share.	31 Jan 2025	442,574	0	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	442,574	442,574	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Ten Percent Owner	Sale or transfer of securities back to the company at price $ 0.00 per share.	31 Jan 2025	442,574	0	-		-	Stock Options
Stabilis Soln Inc - Registered Shares	Westervelt T. Ballard	Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	442,574	442,574	-		-	Stock Options
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	440,000	440,000	-		-	Stock Option (Right to Buy)
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	406,820	6,660,957	-		0	Class A Common Stock
Solid Biosciences Inc	Alexander G. Cumbo	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	401,600	401,600	-		-	Restricted Stock Units
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Michelle D. Gass	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	399,606	399,606	-		-	Stock Appreciation Rights
Kosmos Energy Ltd	Nealesh D. Shah	SVP and CFO		31 Jan 2025	389,237	1,768,567 (0%)	0%		0	Common Stock
Heron Therapeutics Inc	William P. Forbes	EVP, Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	374,220	374,220	-		-	Employee Stock Option (Right to Buy)
Heron Therapeutics Inc	Ira Duarte	EVP, Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	374,220	374,220	-		-	Employee Stock Option (Right to Buy)
Kosmos Energy Ltd	Christopher J. Ball	SVP, Chief Commercial Officer		31 Jan 2025	354,638	1,863,407 (0%)	0%		0	Common Stock
Akebia Therapeutics Inc	John P. Butler	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	350,500	350,500	-		-	Performance Stock Units
Nextcure Inc	Michael S. Richman	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	305,500	305,500	-		-	Employee Stock Option (Right to Buy)
Contineum Therapeutics Inc (Class A)	Carmine Stengone	Director, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	300,000	300,000	-		-	Stock Option (right to buy)
Xeris Biopharma Holdings Inc	Beth P. Hecht	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	300,000	300,000	-		-	Stock Appreciation Right
Xeris Biopharma Holdings Inc	Steven M. Pieper	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	300,000	300,000	-		-	Stock Appreciation Right
Akebia Therapeutics Inc	Steven Keith Burke	SVP, Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	292,300	292,300	-		-	Stock Option (Right to buy)
Akebia Therapeutics Inc	Erik John Ostrowski	SVP, CFO, CBO & Treasurer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	292,300	292,300	-		-	Stock Option (Right to buy)
Akebia Therapeutics Inc	Nicholas Grund	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	292,300	292,300	-		-	Stock Option (Right to buy)
Genelux Corp	Matthew Pulisic	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	275,000	275,000	-		-	Stock Option (right to buy)
Adicet Bio Inc	Donald Healey	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	275,000	275,000	-		-	Stock Option (Right to Buy)
Adicet Bio Inc	Blake Aftab	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	275,000	275,000	-		-	Stock Option (Right to Buy)
Kosmos Energy Ltd	Andrew G. Inglis	Director, Chairman and CEO		31 Jan 2025	270,600	3,647,416 (0%)	0%		0	Common Stock
Travere Therapeutics Inc	Eric M. Dube	Director, CHIEF EXECUTIVE OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	260,000	260,000	-		-	Employee stock option (right to buy)
Ares Management Corp (Class A)	Michael J. Arougheti	Director, Co-Founder, CEO and President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	250,000	1,625,000 (1%)	0%		0	Class A Common Stock
Ares Management Corp (Class A)	R. Kipp DeVeer	Director, Head of Credit Group	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	250,000	1,325,000 (1%)	0%		0	Class A Common Stock
Beta Bionics Inc	Mike Mensinger	Chief Product Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	236,553	236,553	-		-	Employee Stock Option (right to buy)
Zevra Therapeutics Inc	Neil F. McFarlane	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	233,333	283,333 (0%)	0%		-	Common Stock
Zevra Therapeutics Inc	Neil F. McFarlane	Director, President and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	233,333	466,667	-		-	Restricted Stock Unit
Corbus Pharma Holdings Inc	Yuval Cohen	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	228,800	228,800	-		-	Stock options (right to buy)
Netgear Inc	Charles Prober	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	227,910	685,437 (2%)	0%		-	Common Stock
Netgear Inc	Charles Prober	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	227,910	303,880	-		-	Performace Restricted Stock Units
Calix Inc Results Board Meeting	Michael Weening	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	217,500	217,500	-		-	Stock Option (right to buy)
Atea Pharma Inc	Andrea J. Corcoran	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	200,000	200,000	-		-	Stock Option (Right to Buy)
Atea Pharma Inc	Janet Hammond	Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	200,000	200,000	-		-	Stock Option (Right to Buy)
Postal Realty Trust Inc - Ordinary Shares Cls A	Andrew Spodek	Director, CEO and Director, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	198,335	958,196	-		-	LTIP Units
Calix Inc Results Board Meeting	Shane Todd Marshall Eleniak	Chief Product Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	195,000	195,000	-		-	Stock Option (right to buy)
Calix Inc Results Board Meeting	John Matthew Collins	Chief Commercial Ops Officer		31 Jan 2025	195,000	195,000	-		-	Stock Option (right to buy)
Akebia Therapeutics Inc	Steven Keith Burke	SVP, Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	194,900	866,740 (0%)	0%		0	Common Stock
Akebia Therapeutics Inc	Erik John Ostrowski	SVP, CFO, CBO & Treasurer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	194,900	544,900 (0%)	0%		0	Common Stock
Akebia Therapeutics Inc	Nicholas Grund	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	194,900	498,200 (0%)	0%		0	Common Stock
Atea Pharma Inc	Maria Arantxa Horga	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	192,800	192,800	-		-	Stock Option (Right to Buy)
Kinder Morgan (Class P) Results Board Meeting	John W. Schlosser	V.P. (President, Terminals)	Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.48 per share.	31 Jan 2025	187,575	296,142 (0%)	0%	27.5	5,154,561	Class P Common Stock
Heron Therapeutics Inc	William P. Forbes	EVP, Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	187,110	187,110	-		-	Restricted Stock Units
Heron Therapeutics Inc	Ira Duarte	EVP, Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	187,110	187,110	-		-	Restricted Stock Units
Brandywine Realty Trust Results Board Meeting	Gerard H. Sweeney	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	186,713	2,505,948 (1%)	0%	5.5	1,025,054	Common Shares of Beneficial Interest
Beta Bionics Inc	Stephen Feider	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	186,203	186,203	-		-	Employee Stock Option (right to buy)
JPMC	James S. Dimon	Director, Chairman & CEO	Gift of securities by or to the insider at price $ 0.00 per share.	31 Jan 2025	185,936	273,035 (0%)	0%		0	Common Stock
Xeris Biopharma Holdings Inc	Beth P. Hecht	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	185,000	1,393,510 (5%)	0%		0	Common Stock
Xeris Biopharma Holdings Inc	Steven M. Pieper	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	185,000	1,417,561 (5%)	0%		0	Common Stock
Xeris Biopharma Holdings Inc	Kevin McCulloch	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	185,000	1,684,318 (6%)	0%		0	Common Stock
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	181,519	181,520	-		0	Class A Common Stock
Walmart	C. Douglas McMillon	Director, President and CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	179,119	3,587,371 (0%)	0%	98.7	17,670,176	Common Stock
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	173,467	290,024	-		-	Common Stock
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	173,467	173,466	-		-	Restricted Stock Units
Calix Inc Results Board Meeting	Cory J. Sindelar	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	170,000	170,000	-		-	Stock Option (right to buy)
Solid Biosciences Inc	David Tyronne Howton	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	169,100	169,100	-		-	Restricted Stock Units
Beta Bionics Inc	Stephen Feider	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	166,542	166,542	-		-	Employee Stock Option (right to buy)
Karyopharm Therapeutics Inc	Lori Macomber	EVP, CFO & Treasurer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	160,000	160,000 (0%)	0%		0	Common Stock
Immunome Inc	Clay B. Siegall	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 7.75 per share.	31 Jan 2025	150,000	669,636	-	7.8	1,162,500	Common Stock
Kosmos Energy Ltd	Nealesh D. Shah	SVP and CFO		31 Jan 2025	148,500	1,379,330 (0%)	0%		0	Common Stock
Gilead Sciences	Andrew D. Dickinson	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 97.22 per share.	31 Jan 2025	142,180	129,873 (0%)	0%	97.2	13,822,740	Common Stock
Urban Edge Properties	Jeffrey S. Olson	Director, Chairman of the Board & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	139,760	139,760	-		-	2024 LTIP Units
Brandywine Realty Trust Results Board Meeting	Gerard H. Sweeney	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	133,573	2,452,808 (1%)	0%		0	Common Shares of Beneficial Interest
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Michelle D. Gass	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	133,202	559,979 (0%)	0%		0	Class A Common Stock
Atea Pharma Inc	John Vavricka	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	132,800	132,800	-		-	Stock Option (Right to Buy)
Solid Biosciences Inc	Kevin Tan	CFO & Treasurer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	132,300	132,300	-		-	Restricted Stock Units
Travere Therapeutics Inc	Eric M. Dube	Director, CHIEF EXECUTIVE OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	130,000	481,239 (1%)	0%		0	Common Stock
Akebia Therapeutics Inc	Richard C. Malabre	SVP, Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	128,000	128,000	-		-	Stock Option (Right to buy)
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Harmit J. Singh	EVP & Chief Fin. & Growth Ofc.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	126,189	126,189	-		-	Stock Appreciation Rights
Calix Inc Results Board Meeting	Michael Weening	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	125,737	125,737	-		-	Stock Option (right to buy)
Atea Pharma Inc	Wayne Foster	EVP, Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	120,100	120,100	-		-	Stock Option (Right to Buy)
Nextcure Inc	Steven P. Cobourn	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	117,375	117,375	-		-	Employee Stock Option (Right to Buy)
Nextcure Inc	Sol Langermann	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	117,375	117,375	-		-	Employee Stock Option (Right to Buy)
Nextcure Inc	Timothy Mayer	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	117,375	117,375	-		-	Employee Stock Option (Right to Buy)
Urban Edge Properties	Jeffrey S. Olson	Director, Chairman of the Board & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	116,127	116,127	-		-	LTIP Units (2025 LTI Time)
Netgear Inc	Charles Prober	Director, Chief Exective Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	115,733	571,553 (1%)	0%		0	Common Stock
Netgear Inc	Charles Prober	Director, Chief Exective Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.65 per share.	31 Jan 2025	115,733	455,820 (1%)	0%	27.6	3,200,017	Common Stock
Netgear Inc	Charles Prober	Director, Chief Exective Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	115,733	340,087	-		-	Performance Restricted Units
Netgear Inc	Charles Prober	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.65 per share.	31 Jan 2025	115,733	569,704 (1%)	0%	27.6	3,200,017	Common Stock
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Gianluca Flore	EVP & Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	115,674	115,674	-		-	Stock Appreciation Rights
Surgery Partners Inc	Harrison R. Bane	National Group President		31 Jan 2025	115,116	163,352 (0%)	0%		0	Common Stock
Grindr Inc (Class A)	J. Michael Gearon	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 0.00 per share.	31 Jan 2025	114,459	255,941	-		-	Warrants
Ares Management Corp (Class A)	Michael J. Arougheti	Director, Co-Founder, CEO and President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 198.22 per share.	31 Jan 2025	114,155	1,510,845 (1%)	0%	198.2	22,627,804	Class A Common Stock
Solid Biosciences Inc	Gabriel Brooks	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	112,900	112,900	-		-	Restricted Stock Units
Surgery Partners Inc	J. Eric Evans	Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	111,048	587,218 (1%)	0%		0	Common Stock
Xeris Biopharma Holdings Inc	John P. Shannon	Director, See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	110,750	1,997,868 (7%)	0%	3.6	394,270	Common Stock
Xeris Biopharma Holdings Inc	John P. Shannon	Director, See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	110,750	1,887,118 (6%)	0%	3.6	394,270	Common Stock
Xeris Biopharma Holdings Inc	Steven M. Pieper	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	110,750	1,299,011 (4%)	0%	3.6	394,270	Common Stock
Solid Biosciences Inc	Jessie Hanrahan	Chief Regulatory Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,500	110,500	-		-	Restricted Stock Units
Beta Bionics Inc	Mike Mensinger	Chief Product Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,278	110,278	-		-	Employee Stock Option (right to buy)
Jackson Fin Inc (Class A)	Laura L. Prieskorn	Director, CEO, President and Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,222	468,638	-		0	Common Stock
Contineum Therapeutics Inc (Class A)	Peter T. Slover	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,000	110,000	-		-	Stock Option (right to buy)
Contineum Therapeutics Inc (Class A)	Daniel S. Lorrain	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,000	110,000	-		-	Stock Option (right to buy)
Contineum Therapeutics Inc (Class A)	Stephen L. Huhn	CMO & Sr VP, Clinical Dev.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	110,000	110,000	-		-	Stock Option (right to buy)
Beta Bionics Inc	Stephen Feider	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	109,695	109,695	-		-	Employee Stock Option (right to buy)
Calix Inc Results Board Meeting	Cory J. Sindelar	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	107,775	107,775	-		-	Stock Option (right to buy)
Calix Inc Results Board Meeting	Shane Todd Marshall Eleniak	Chief Product Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	107,775	107,775	-		-	Stock Option (right to buy)
Calix Inc Results Board Meeting	John Matthew Collins	Chief Commercial Ops Officer		31 Jan 2025	107,775	107,775	-		-	Stock Option (right to buy)
PACCAR Results Board Meeting	Darrin C. Siver	EXECUTIVE VICE PRESIDENT	Sale of securities on an exchange or to another person at price $ 111.56 per share.	31 Jan 2025	103,671	61,005 (0%)	0%	111.6	11,565,682	Common Stock
Kosmos Energy Ltd	Andrew G. Inglis	Director, Chairman and CEO		31 Jan 2025	102,701	4,236,691 (1%)	0%	3.1	320,427	Common Stock
Hims & Hers Health Inc (Class A)	Andrew Dudum	Director, Chief Executive Officer, Ten Percent Owner	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	100,000	1,406,401	-		-	Stock Option (right to buy)
Hims & Hers Health Inc (Class A)	Andrew Dudum	Director, Chief Executive Officer, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 35.22 per share.	31 Jan 2025	100,000	27,918	-	35.2	3,522,300	Class A Common Stock
Hims & Hers Health Inc (Class A)	Andrew Dudum	Director, Chief Executive Officer, Ten Percent Owner	Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.43 per share.	31 Jan 2025	100,000	127,918	-	2.4	243,000	Class A Common Stock
Travere Therapeutics Inc	Jula Inrig	CHIEF MEDICAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	100,000	100,000	-		-	Employee stock option (right to buy)
Kosmos Energy Ltd	Christopher J. Ball	SVP, Chief Commercial Officer		31 Jan 2025	99,525	1,508,769 (0%)	0%		0	Common Stock
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	99,518	99,518	-		-	Restricted Stock Units
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	99,517	389,541	-		-	Common Stock
Solid Biosciences Inc	Paul Herzich	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	98,700	98,700	-		-	Restricted Stock Units
Xeris Biopharma Holdings Inc	Beth P. Hecht	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	98,375	1,208,510 (4%)	0%	3.6	350,215	Common Stock
Akebia Therapeutics Inc	John P. Butler	Director, CEO and President	Sale of securities on an exchange or to another person at price $ 2.10 per share.	31 Jan 2025	97,982	2,604,330 (2%)	0%	2.1	205,762	Common Stock
Nutriband Inc	Gareth Sheridan	Director, Chief Executive Officer, Ten Percent Owner		31 Jan 2025	97,500	251,000	-		-	Stock Option
Stryker	Ronda E. Stryker	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 390.89 per share.	31 Jan 2025	96,728	3,746,739 (1%)	0%	390.9	37,810,008	Common Stock
UroGen Pharma Ltd	Elizabeth Barrett	Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	96,377	96,377	-		-	Restricted Stock Units
Ares Management Corp (Class A)	R. Kipp DeVeer	Director, Head of Credit Group	Payment of exercise price or tax liability using portion of securities received from the company at price $ 198.22 per share.	31 Jan 2025	96,067	1,228,933 (1%)	0%	198.2	19,042,401	Class A Common Stock
NexPoint Diversified Real Estate Trust	James D. Dondero	Director, See Remarks, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	95,314	1,556,809 (3%)	0%		-	Common Stock
Walmart	John R. Furner	Executive Vice President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	94,829	473,797 (0%)	0%	98.7	9,354,889	Common
Walmart	John David Rainey	Executive Vice President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	93,392	295,281 (0%)	0%	98.7	9,213,195	Common
Corbus Pharma Holdings Inc	Sean F. Moran	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	92,500	92,500	-		-	Stock options (right to buy)
Corbus Pharma Holdings Inc	Dominic Smethurst	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	91,200	91,200	-		-	Stock options (right to buy)
Postal Realty Trust Inc - Ordinary Shares Cls A	Jeremy Garber	Pres., Treasurer & Secretary	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	90,909	217,888	-		-	LTIP Units
Beta Bionics Inc	Steven Russell	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	90,637	90,637	-		-	Employee Stock Option (right to buy)
NexPoint Diversified Real Estate Trust	James D. Dondero	Director, See Remarks, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	90,327	1,461,495 (3%)	0%		-	Common Stock
Atea Pharma Inc	Jean-Pierre Sommadossi	Director, President, CEO, and Chairman	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share.	31 Jan 2025	88,601	300,940	-	3.1	271,119	Common Stock
Immersion Corp Dividend	William C. Martin	Director, Chief Strategy Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	86,899	1,423,543 (4%)	0%		0	Common Stock
Walmart	Suresh Kumar	Chief Technology Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	86,278	1,317,753 (0%)	0%	98.7	8,511,327	Common
Akebia Therapeutics Inc	Richard C. Malabre	SVP, Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	85,000	310,450 (0%)	0%		0	Common Stock
Beta Bionics Inc	Sean Saint	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	83,268	83,268	-		-	Employee Stock Option (right to buy)
Beta Bionics Inc	Mark Hopman	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	83,242	83,242	-		-	Employee Stock Option (right to buy)
Beta Bionics Inc	Steven Russell	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	81,217	81,217	-		-	Employee Stock Option (right to buy)
Calix Inc Results Board Meeting	Michael Weening	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	80,325	80,325	-		-	Stock Option (right to buy)
Ramaco Resources Inc (Class A)	Randall W. Atkins	Director, CHIEF EXECUTIVE OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	79,132	570,031	-		0	Class A common stock
Walmart	Kathryn McLay	Executive Vice President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	79,022	692,865 (0%)	0%	98.7	7,795,613	Common
Bentley Systems Inc (Class B)	Nicholas H. Cumins	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 46.55 per share.	31 Jan 2025	77,161	428,084	-	46.6	3,591,845	Class B Common Stock
Intel Results Board Meeting	David A. Zinsner	Interim Co-CEO, EVP, CFO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	75,682	0	-		-	Restricted Stock Units
Intel Results Board Meeting	David A. Zinsner	Interim Co-CEO, EVP, CFO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	75,682	234,182 (0%)	0%		-	Common Stock
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	75,000	140,663	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	75,000	659,132 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	75,000	215,663	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	75,000	698,896 (0%)	0%		-	Class A common stock
Liberty Latin America Ltd (Class A)	John M. Winter	SVP, CLO AND SECRETARY	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	74,812	369,258 (0%)	0%		0	Class C Common Shares
Brandywine Realty Trust Results Board Meeting	Gerard H. Sweeney	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	72,063	2,570,088 (1%)	0%		0	Common Shares of Beneficial Interest
NexPoint Diversified Real Estate Trust	James D. Dondero	Director, See Remarks, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	71,910	1,628,720 (3%)	0%		-	Common Stock
Gilead Sciences	Andrew D. Dickinson	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	71,850	0	-		-	Non-qualified Stock Option (Right to Buy)
Gilead Sciences	Andrew D. Dickinson	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.34 per share.	31 Jan 2025	71,850	227,893 (0%)	0%	72.3	5,197,629	Common Stock
Xcel Brands Inc	Robert W. D'Loren	Director, CEO and Chairman, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.42 per share.	31 Jan 2025	70,016	2,217,183 (11%)	0%	0.4	29,617	Common Stock
Beam Therapeutics Inc	Giuseppe Ciaramella	President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	70,000	70,000	-		-	Stock Option (Right to Buy)
Ares Management Corp (Class A)	Jarrod Phillips	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	70,000	253,328 (0%)	0%		0	Class A Common Stock
Calix Inc Results Board Meeting	Cory J. Sindelar	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	68,850	68,850	-		-	Stock Option (right to buy)
Calix Inc Results Board Meeting	Shane Todd Marshall Eleniak	Chief Product Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	68,850	68,850	-		-	Stock Option (right to buy)
Calix Inc Results Board Meeting	John Matthew Collins	Chief Commercial Ops Officer		31 Jan 2025	68,850	68,850	-		-	Stock Option (right to buy)
Corbus Pharma Holdings Inc	Yuval Cohen	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	68,100	145,321 (0%)	0%		0	Common Stock, par value $0.0001 per share
Customers Bancorp Inc Results	Jay S. Sidhu	Director, Chairman & CEO	Sale of securities on an exchange or to another person at price $ 56.82 per share.	31 Jan 2025	67,000	965,723 (3%)	0%	56.8	3,806,846	Common Stock
Xeris Biopharma Holdings Inc	Steven M. Pieper	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	66,450	1,232,561 (4%)	0%	3.6	236,562	Common Stock
BigBear.ai Holdings Inc	Carolyn Blankenship	General Counsel and Secretary	Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.24 per share.	31 Jan 2025	66,153	492,505	-	4.2	280,489	Common Stock
Nextcure Inc	Sourav Kundu	Sr VP, Dev. & Mfg.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	66,125	66,125	-		-	Employee Stock Option (Right to Buy)
Nextcure Inc	Kevin G. Shaw	Sr VP, General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	66,125	66,125	-		-	Employee Stock Option (Right to Buy)
CNX Resources Corp Analyst Upgrade	Nicholas J. DeIuliis	Director, President and CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.38 per share.	31 Jan 2025	64,883	2,374,798 (1%)	0%	27.4	1,776,497	Common shares, $0.01 par value per share
Boston Properties Inc	Owen D. Thomas	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	64,602	835,408	-		-	LTIP Units
CNX Resources Corp Analyst Upgrade	Nicholas J. DeIuliis	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	64,338	2,420,193 (1%)	0%		0	Common shares, $0.01 par value per share
Urban Edge Properties	Jeffrey Mooallem	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	64,011	64,011	-		-	2024 LTIP Units
Urban Edge Properties	Mark J. Langer	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	63,704	63,704	-		-	2024 LTIP Units
Contineum Therapeutics Inc (Class A)	John Stephen Healy	General Counsel and Corp Sec	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	63,589	63,589	-		-	Stock Option (right to buy)
TKO (Class A)	Ariel Z. Emanuel	Director, Chief Executive Officer, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 157.78 per share.	31 Jan 2025	62,597	1,759,968	-	157.8	9,876,555	Class A Common Stock
Apollo Commercial Real Estate Finance Inc	Stuart A. Rothstein	Director, President & CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share.	31 Jan 2025	62,190	438,002 (0%)	0%	9.1	564,063	Common Stock
Brandywine Realty Trust Results Board Meeting	Thomas E. Wirth	Executive Vice President & CFO	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	60,813	574,176 (0%)	0%	5.5	333,863	Common Shares of Beneficial Interest
TXO Energy Partners L.P. - Units Board Meeting	Brent W. Clum	Director, Pres, Business Opers and CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	60,200	478,039	-		0	Common Units
Zentalis Pharma Inc High Gain High Volume	Jan Skvarka	Director	Purchase of securities on an exchange or from another person at price $ 1.72 per share.	31 Jan 2025	60,000	149,551	-	1.7	103,446	Common Stock
Solid Biosciences Inc	Ilan Ganot	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	60,000	60,000	-		-	Restricted Stock Units
TKO (Class A)	Ariel Z. Emanuel	Director, Chief Executive Officer, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 156.84 per share.	31 Jan 2025	59,784	1,840,313	-	156.8	9,376,523	Class A Common Stock
Travere Therapeutics Inc	Elizabeth E. Reed	SVP, GC & CORPORATE SECRETARY	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	58,000	58,000	-		-	Employee stock option (right to buy)
Travere Therapeutics Inc	William E. Rote	SENIOR VICE PRESIDENT, R&D	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	58,000	58,000	-		-	Employee stock option (right to buy)
Travere Therapeutics Inc	Peter Heerma	CHIEF COMMERCIAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	58,000	58,000	-		-	Employee stock option (right to buy)
Travere Therapeutics Inc	Christopher Cline	CHIEF FINANCIAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	58,000	58,000	-		-	Employee stock option (right to buy)
Deluxe Corp	Barry C. McCarthy	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	57,343	238,303 (0%)	0%		0	Common Stock
Kosmos Energy Ltd	Nealesh D. Shah	SVP and CFO		31 Jan 2025	56,987	1,711,580 (0%)	0%	3.1	177,799	Common Stock
CareTrust REIT Inc 10-year high	David M. Sedgwick	President and CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.50 per share.	31 Jan 2025	56,378	446,143 (0%)	0%	26.5	1,494,017	Common Stock
Beta Bionics Inc	Sean D. Carney	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	55,837	55,837	-		-	Director Stock Option (right to buy)
Akebia Therapeutics Inc	Nicholas Grund	Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 2.10 per share.	31 Jan 2025	55,621	442,579 (0%)	0%	2.1	116,804	Common Stock
Beam Therapeutics Inc	Amy Simon	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	55,000	55,000	-		-	Stock Option (Right to Buy)
Beta Bionics Inc	Sean Saint	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	54,911	54,911	-		-	Employee Stock Option (right to buy)
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Elizabeth O’Neill	EVP & Chief Operations Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	54,681	54,681	-		-	Stock Appreciation Rights
Usio Inc	Houston Frost	SVP, Chief Product Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share.	31 Jan 2025	54,460	660,567 (3%)	0%	1.9	102,385	Common Stock
Beta Bionics Inc	Steven Russell	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	53,584	53,584	-		-	Employee Stock Option (right to buy)
Cohen & Steers Inc	Joseph M. Harvey	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	53,240	1,283,645 (2%)	0%		0	Common Stock
Kosmos Energy Ltd	Josh R. Marion	SVP and General Counsel		31 Jan 2025	52,800	136,561 (0%)	0%		0	Common Stock
TXO Energy Partners L.P. - Units Board Meeting	Gary D. Simpson	President, Prod & Development	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	52,770	231,480	-		0	Common Units
TXO Energy Partners L.P. - Units Board Meeting	Brent W. Clum	Director, Pres, Business Opers and CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	52,770	417,839	-		0	Common Units
Netgear Inc	Charles Prober	Director, Chief Exective Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.65 per share.	31 Jan 2025	52,661	404,866 (1%)	0%	27.7	1,456,077	Common Stock
Netgear Inc	Charles Prober	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.65 per share.	31 Jan 2025	52,661	517,043 (1%)	0%	27.7	1,456,077	Common Stock
Brandywine Realty Trust Results Board Meeting	Gerard H. Sweeney	Director, President and CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.49 per share.	31 Jan 2025	52,253	2,319,235 (1%)	0%	5.5	286,869	Common Shares of Beneficial Interest
EVgo Inc (Class A)	Dennis G. Kish	President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	52,083	52,084	-		-	Restricted Stock Units
EVgo Inc (Class A)	Dennis G. Kish	President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	52,083	140,170	-		-	Class A Common Stock
Otis Worldwide Results Board Meeting	Peiming Zheng	EVP, Chief Product, Delivery		31 Jan 2025	51,965	67,535	-	63.9	3,321,603	Common Stock
Otis Worldwide Results Board Meeting	Peiming Zheng	EVP, Chief Product, Delivery		31 Jan 2025	51,965	0	-		-	Stock Appreciation Right
Kosmos Energy Ltd	Ronald W. Glass	VP & Chief Accounting Officer		31 Jan 2025	51,640	336,413 (0%)	0%		0	Common Stock
Kosmos Energy Ltd	Josh R. Marion	SVP and General Counsel		31 Jan 2025	51,640	188,201 (0%)	0%		0	Common Stock
Stryker	Ronda E. Stryker	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 394.85 per share.	31 Jan 2025	51,454	3,630,738 (0%)	0%	394.9	20,316,612	Common Stock
Urban Edge Properties	Jeffrey S. Olson	Director, Chairman of the Board & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	51,008	51,008	-		-	LTIP Units (2025 LTI Perf.)
Travere Therapeutics Inc	Eric M. Dube	Director, CHIEF EXECUTIVE OFFICER	Sale of securities on an exchange or to another person at price $ 20.21 per share.	31 Jan 2025	50,691	430,548 (0%)	0%	20.2	1,024,343	Common Stock
Public Storage	John Reyes	Director		31 Jan 2025	50,000	53,275	-		-	AO LTIP Units
Kosmos Energy Ltd	Ronald W. Glass	VP & Chief Accounting Officer		31 Jan 2025	50,000	284,773 (0%)	0%		0	Common Stock
Sanuwave Health Inc	Morgan C. Frank	Director, Chief Executive Officer, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	50,000	50,000	-		-	Stock Option (right to buy)
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	49,765	821,576	-		0	Class A Common Stock
Brandywine Realty Trust Results Board Meeting	H. Jeffrey Devuono	EVP & Senior Managing Director	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	48,887	498,881 (0%)	0%	5.5	268,390	Common Shares of Beneficial Interest
Xeris Biopharma Holdings Inc	Kevin McCulloch	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	48,834	1,499,318 (5%)	0%	3.6	173,849	Common Stock
Beta Bionics Inc	Christy Jones	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	48,730	48,730	-		-	Director Stock Option (right to buy)
Cousins Properties Inc	Michael Colin Connolly	President & CEO	Grant, award, or other acquisition of securities at price $ 30.53 per share.	31 Jan 2025	48,506	346,692 (0%)	0%	30.5	1,480,888	Common Stock
Ramaco Resources Inc (Class A)	Randall W. Atkins	Director, CHIEF EXECUTIVE OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	48,235	48,234	-		-	Restricted Stock Units
Beta Bionics Inc	Mark Hopman	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	47,775	47,775	-		-	Employee Stock Option (right to buy)
Atea Pharma Inc	Janet Hammond	Chief Development Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	46,800	84,272	-		-	Common Stock
Atea Pharma Inc	Janet Hammond	Chief Development Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	46,800	46,800	-		-	Restricted Stock Units
Boston Properties Inc	Douglas T. Linde	Director, President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	46,486	613,628	-		-	LTIP Units
Bentley Systems Inc (Class B)	David R. Shaman	Chief Legal Officer	Grant, award, or other acquisition of securities at price $ 46.55 per share.	31 Jan 2025	46,297	724,439	-	46.5	2,155,125	Class B Common Stock
Akebia Therapeutics Inc	John P. Butler	Director, CEO and President	Sale of securities on an exchange or to another person at price $ 2.10 per share.	31 Jan 2025	46,268	2,702,312 (2%)	0%	2.1	97,163	Common Stock
Xeris Biopharma Holdings Inc	Beth P. Hecht	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	45,909	1,306,885 (4%)	0%	3.6	163,436	Common Stock
Brandywine Realty Trust Results Board Meeting	William D. Redd	EVP & Senior Managing Director	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	45,641	357,791 (0%)	0%	5.5	250,569	Common Shares of Beneficial Interest
Leonardo DRS Inc	William J. Lynn	Director, Chief Executive Officer		31 Jan 2025	45,000	189,937	-	35.3	1,586,250	Common Stock
MSCI Results Board Meeting	Henry A. Fernandez	Director, Chairman and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	44,920	44,920	-		-	Premium option to purchase common stock
CubeSmart	Christopher P. Marr	Director, CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.70 per share.	31 Jan 2025	44,761	594,491 (0%)	0%	41.7	1,866,534	Common
Atea Pharma Inc	Andrea J. Corcoran	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	44,367	44,366	-		-	Restricted Stock Units
Atea Pharma Inc	Andrea J. Corcoran	See Remarks	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	44,367	722,909	-		-	Common Stock
EVgo Inc (Class A)	Dennis G. Kish	President	Sale of securities on an exchange or to another person at price $ 3.41 per share.	31 Jan 2025	44,184	95,986	-	3.4	150,557	Class A Common Stock
Gilead Sciences	Andrew D. Dickinson	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	44,160	0	-		-	Non-qualified Stock Option (Right to Buy)
Gilead Sciences	Andrew D. Dickinson	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.38 per share.	31 Jan 2025	44,160	273,053 (0%)	0%	65.4	2,887,181	Common Stock
Brandywine Realty Trust Results Board Meeting	George D. Johnstone	EVP, Operations	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	44,158	460,882 (0%)	0%	5.5	242,427	Common Shares of Beneficial Interest
Lightpath Tech Inc (Class A)	Steven Eric Creviston	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	43,796	152,057 (0%)	0%		-	Class A common stock
Lightpath Tech Inc (Class A)	Kimberly Crider	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	43,796	43,796 (0%)	0%		-	Class A common stock
Brandywine Realty Trust Results Board Meeting	Thomas E. Wirth	Executive Vice President & CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	43,504	556,867 (0%)	0%		0	Common Shares of Beneficial Interest
Innovative Soln And Support Inc	Christopher Harborne	Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 11.84 per share.	31 Jan 2025	42,788	2,374,983 (13%)	0%	11.8	506,773	Common Stock, par value $0.001 per share
BlackRock Corporate High Yield Fund Inc Board Meeting	Mitchell Garfin	Portfolio Manager	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	42,606	42,606	-		-	Phantom Shares
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	42,273	42,273	-		0	Class A Common Stock
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Harmit J. Singh	EVP & Chief Fin. & Growth Ofc.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	42,063	331,791 (0%)	0%		0	Class A Common Stock
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	David Jedrzejek	SVP and General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	42,063	42,063	-		-	Stock Appreciation Rights
Chevron	Michael K. Wirth	Director, Chairman and CEO	Sale or transfer of securities back to the company at price $ 149.19 per share.	31 Jan 2025	41,893	4,325 (0%)	0%	149.2	6,250,017	Common Stock
Chevron	Michael K. Wirth	Director, Chairman and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	41,893	0	-		-	Restricted Stock Units
Chevron	Michael K. Wirth	Director, Chairman and CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	41,893	46,218 (0%)	0%		0	Common Stock
Ardelyx Inc	Michael G. Raab	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 5.36 per share.	31 Jan 2025	41,666	1,108,719 (1%)	0%	5.4	223,355	Common Stock
Atea Pharma Inc	Maria Arantxa Horga	Chief Medical Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	41,533	41,533	-		-	Restricted Stock Units
Atea Pharma Inc	Maria Arantxa Horga	Chief Medical Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	41,533	67,197	-		-	Common Stock
MSCI Results Board Meeting	Henry A. Fernandez	Director, Chairman and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	40,780	40,780	-		-	Premium option to purchase common stock
Beam Therapeutics Inc	Christine Bellon	Chief Legal Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	40,000	40,000	-		-	Stock Option (Right to Buy)
Ares Management Corp (Class A)	Ryan Berry	Chief Mktg. & Strategy Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	40,000	240,229 (0%)	0%		0	Class A Common Stock
Beta Bionics Inc	Mark Hopman	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	39,424	39,424	-		-	Employee Stock Option (right to buy)
UMB Fin Corp	J. Mariner Kemper	Director, Chairman and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	39,329	329,060 (0%)	0%		0	Common Stock
Cognition Therapeutics Inc	Lisa Ricciardi	Director, CEO & President	Purchase of securities on an exchange or from another person at price $ 0.77 per share.	31 Jan 2025	38,851	38,851	-	0.8	30,001	Common Stock
Stryker	Ronda E. Stryker	Director, Ten Percent Owner	Sale of securities on an exchange or to another person at price $ 391.89 per share.	31 Jan 2025	38,802	3,707,937 (0%)	0%	391.9	15,206,116	Common Stock
Urban Edge Properties	Robert C. Milton	General Counsel and Secretary		31 Jan 2025	38,680	38,680	-		-	2024 LTIP Units
Levi Strauss & Co. - Ordinary Shares Cls A Dividend	Gianluca Flore	EVP & Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	38,558	174,588 (0%)	0%		0	Class A Common Stock
Roblox Corp (Class A)	Anthony P. Lee	Director	Other type of transaction at price $ 0.00 per share.	31 Jan 2025	38,164	38,164	-		0	Class A Common Stock
CareTrust REIT Inc 10-year high	William M. Wagner	CFO and Treasurer		31 Jan 2025	37,797	290,522 (0%)	0%	26.5	1,001,621	Common Stock
Virtu Fin Inc (Class A)	Joseph Molluso	Co-President & Co-COO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	427,188 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Joseph Molluso	Co-President & Co-COO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	443,951 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Joseph Molluso	Co-President & Co-COO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	139,884	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Joseph Molluso	Co-President & Co-COO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	102,384	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Stephen Cavoli	EVP	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	204,421 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Stephen Cavoli	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	222,778 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Stephen Cavoli	EVP	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	137,233	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Stephen Cavoli	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	99,733	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Brett Fairclough	Co-President & Co-COO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	128,249 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Brett Fairclough	Co-President & Co-COO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	154,686 (0%)	0%		-	Class A common stock
Virtu Fin Inc (Class A)	Brett Fairclough	Co-President & Co-COO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	37,500	64,884	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Brett Fairclough	Co-President & Co-COO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,500	102,384	-		-	Restricted Stock Unit
Beta Bionics Inc	Mark Hopman	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	37,229	37,229	-		-	Employee Stock Option (right to buy)
Walmart	Rachel Brand	Executive Vice President		31 Jan 2025	37,027	278,317 (0%)	0%	98.7	3,652,768	Common
MSCI Results Board Meeting	Henry A. Fernandez	Director, Chairman and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,846	36,846	-		-	Premium option to purchase common stock
Natera Inc	Steven Leonard Chapman	Director, CEO AND PRESIDENT	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,682	290,626 (0%)	0%		-	Common Stock
Amarin Corp (ADR)	Peter Fishman	SVP, CFO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	36,667	73,333	-		-	Restricted Stock Unit
Amarin Corp (ADR)	Peter Fishman	SVP, CFO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	36,667	93,573 (0%)	0%		-	Ordinary Shares
Bentley Systems Inc (Class B)	Nicholas H. Cumins	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.55 per share.	31 Jan 2025	36,145	350,923	-	46.6	1,682,550	Class B Common Stock
Abeona Therapeutics Inc	Mark J. Alvino	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	100,435 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Eric Crombez	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	47,145 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Leila Alland	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	154,366 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Christine Berni Silverstein	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	133,572 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Faith L. Charles	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	149,832 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Michael Amoroso	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	180,466 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Donald A. Wuchterl	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	150,612 (0%)	0%		0	Common Stock
Abeona Therapeutics Inc	Bernhardt G. Zeiher	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	36,101	47,145 (0%)	0%		0	Common Stock
Xcel Brands Inc	Robert W. D'Loren	Director, CEO and Chairman, Ten Percent Owner	Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.42 per share.	31 Jan 2025	36,058	2,181,125 (11%)	0%	0.4	15,253	Common Stock
Brandywine Realty Trust Results Board Meeting	Gerard H. Sweeney	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 5.49 per share.	31 Jan 2025	36,032	2,534,057 (1%)	0%	5.5	197,816	Common Shares of Beneficial Interest
Heron Therapeutics Inc	Craig A. Johnson	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Heron Therapeutics Inc	Christian Waage	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Heron Therapeutics Inc	Michael Kaseta	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Heron Therapeutics Inc	Susan Rodriguez	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Heron Therapeutics Inc	Sharmila Dissanaike	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Heron Therapeutics Inc	Adam Morgan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,900	35,900	-		-	Stock Option (Right to Buy)
Bentley Systems Inc (Class B)	Nicholas H. Cumins	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.55 per share.	31 Jan 2025	35,733	392,351	-	46.5	1,663,371	Class B Common Stock
Urban Edge Properties	Jeffrey Mooallem	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,526	35,526	-		-	LTIP Units (2025 LTI Time)
Walmart	Daniel J. Bartlett	Executive Vice President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	35,508	425,196 (0%)	0%	98.7	3,502,932	Common Stock
Walmart	Donna Morris	Executive Vice President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.65 per share.	31 Jan 2025	35,508	359,158 (0%)	0%	98.7	3,502,932	Common
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share.	31 Jan 2025	35,236	623,896 (0%)	0%		-	Class A common stock
Pathfinder Bancorp Inc	Dawd A James	President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	35,000	55,704 (1%)	0%		0	Common Stock
Brandywine Realty Trust Results Board Meeting	H. Jeffrey Devuono	EVP & Senior Managing Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	34,973	484,967 (0%)	0%		0	Common Shares of Beneficial Interest
Otis Worldwide Results Board Meeting	Peiming Zheng	EVP, Chief Product, Delivery		31 Jan 2025	34,672	32,863	-	95.8	3,321,578	Common Stock
BlackRock Innovation & Growth Trust	Philip Ruvinsky	Portfolio Manager	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	34,613	38,219	-		-	Common Stock
BlackRock Innovation & Growth Trust	Philip Ruvinsky	Portfolio Manager	Sale or transfer of securities back to the company at price $ 8.20 per share.	31 Jan 2025	34,613	3,606	-	8.2	283,831	Common Stock
Liberty Latin America Ltd (Class A)	Balan Nair	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	34,570	1,510,874 (3%)	0%		-	Class C Common Shares
Wolfspeed Inc	Thomas H. Werner	Director, Executive Chair, Chairman of the Board	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	34,201	181,888 (0%)	0%		0	COMMON STOCK
PACCAR Results Board Meeting	R. Preston Feight	Director, CHIEF EXECUTIVE OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	34,110	102,330	-		-	Stock Option
PACCAR Results Board Meeting	R. Preston Feight	Director, CHIEF EXECUTIVE OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.87 per share.	31 Jan 2025	34,110	231,329 (0%)	0%	62.9	2,144,383	Common Stock
Beta Bionics Inc	Mike Mensinger	Chief Product Officer	Purchase of securities on an exchange or from another person at price $ 17.00 per share.	31 Jan 2025	33,350	59,019	-	17	566,950	Common Stock
Atea Pharma Inc	Wayne Foster	EVP, Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	54,190	-		-	Common Stock
Atea Pharma Inc	Wayne Foster	EVP, Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	33,333	-		-	Restricted Stock Units
Atea Pharma Inc	John Vavricka	Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	54,848	-		-	Common Stock
Atea Pharma Inc	John Vavricka	Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	33,333	-		-	Restricted Stock Units
Applied Digital Corp	Michael Maniscalco	Former Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	161,192	-		-	Common Stock
Applied Digital Corp	Michael Maniscalco	Former Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,333	133,334	-		-	Restricted Stock Unit
Customers Bancorp Inc Results	Jay S. Sidhu	Director, Chairman & CEO	Sale of securities on an exchange or to another person at price $ 57.25 per share.	31 Jan 2025	33,173	1,032,723 (3%)	0%	57.2	1,899,138	Common Stock
Ramaco Resources Inc (Class A)	Jeremy R. Sussman	CHIEF FINANCIAL OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	33,000	366,184	-		0	Class A common stock
Ramaco Resources Inc (Class A)	Jason Todd Fannin	CHIEF COMMERCIAL OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	32,831	175,175	-		0	Class A common stock
Brandywine Realty Trust Results Board Meeting	William D. Redd	EVP & Senior Managing Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	32,651	344,801 (0%)	0%		0	Common Shares of Beneficial Interest
Cohen & Steers Inc	Joseph M. Harvey	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.83 per share.	31 Jan 2025	32,571	1,230,405 (2%)	0%	88.8	2,893,282	Common Stock
UMB Fin Corp	John K. Schmidt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	32,468	32,468 (0%)	0%		-	Common Stock
Firstsun Cap Bancorp	Diane L. Merdian	Director		31 Jan 2025	31,722	33,399	-	19.7	625,558	Common Stock, $0.0001 par value
Firstsun Cap Bancorp	Diane L. Merdian	Director		31 Jan 2025	31,722	0	-		-	Stock Option, Common Stock, $0.0001 par value
Jackson Fin Inc (Class A)	Craig D. Smith	CEO, CIO & Pres PPM America	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	31,620	159,391	-		0	Common Stock
Ramaco Resources Inc (Class A)	Christopher L. Blanchard	EVP Mine Planning & Developmen	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	31,610	429,905	-		0	Class A common stock
Brandywine Realty Trust Results Board Meeting	George D. Johnstone	EVP, Operations		31 Jan 2025	31,590	448,314 (0%)	0%		0	Common Shares of Beneficial Interest
Ashland Inc	Guillermo Novo	Director, Chair of the Board and CEO	Purchase of securities on an exchange or from another person at price $ 64.24 per share.	31 Jan 2025	31,294	31,294 (0%)	0%	64.2	2,010,327	Common Stock
MasterBrand Inc	R. David Banyard	Director, CEO & President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.82 per share.	31 Jan 2025	31,277	1,132,010	-	17.8	557,356	Common Stock, par value $0.01 per share
Yext Inc	Julie G. Richardson	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	31,250	147,055 (0%)	0%		-	Common Stock
Yext Inc	Julie G. Richardson	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	31,250	0	-		-	Restricted Stock Unit
Virtu Fin Inc (Class A)	Douglas A. Cifu	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share.	31 Jan 2025	31,175	667,721 (0%)	0%		-	Class A common stock
Ramaco Resources Inc (Class A)	Randall W. Atkins	Director, CHIEF EXECUTIVE OFFICER	Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.64 per share.	31 Jan 2025	31,138	538,893	-	9.6	300,170	Class A common stock
Liberty Latin America Ltd (Class A)	John M. Winter	SVP, CLO AND SECRETARY	Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.13 per share.	31 Jan 2025	31,067	338,191 (0%)	0%	6.1	190,441	Class C Common Shares
Meta	Mark Zuckerberg	Director, COB and CEO, Ten Percent Owner		31 Jan 2025	30,908	193,236,175	-		-	Class B Common Stock
Meta	Mark Zuckerberg	Director, COB and CEO, Ten Percent Owner		31 Jan 2025	30,908	30,908 (0%)	0%		0	Class A Common Stock
Ramaco Resources Inc (Class A)	Randall W. Atkins	Director, CHIEF EXECUTIVE OFFICER	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	30,897	61,794	-		-	Restricted Stock Units
Ally Fin Inc Results Board Meeting	Russell E. Hutchinson	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 39.06 per share.	31 Jan 2025	30,722	228,221 (0%)	0%	39.1	1,200,001	Common Stock
IZEA Worldwide Inc	Patrick J. Venetucci	Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	30,650	429,100	-		-	Restricted Stock Units
IZEA Worldwide Inc	Patrick J. Venetucci	Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	30,650	151,762 (0%)	0%		0	Common Stock
TKO (Class A)	Ariel Z. Emanuel	Director, Chief Executive Officer, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 156.62 per share.	31 Jan 2025	30,630	1,659,710	-	156.6	4,797,271	Class A Common Stock
Apartment Investment & Management Co. (Class A)	H. Lynn C. Stanfield	EVP and CFO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.04 per share.	31 Jan 2025	30,578	524,540	-	9.0	276,425	Class A Common Stock
Beta Bionics Inc	Sean D. Carney	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	30,456	30,456	-		-	Director Stock Option (right to buy)
Akebia Therapeutics Inc	Richard C. Malabre	SVP, Chief Accounting Officer	Sale of securities on an exchange or to another person at price $ 2.10 per share.	31 Jan 2025	30,202	280,248 (0%)	0%	2.1	63,424	Common Stock
Intel Results Board Meeting	David A. Zinsner	Interim Co-CEO, EVP, CFO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.86 per share.	31 Jan 2025	30,042	204,140 (0%)	0%	19.9	596,634	Common Stock
Corning	Eric S. Musser	President and COO	Sale of securities on an exchange or to another person at price $ 51.92 per share.	31 Jan 2025	30,000	152,944 (0%)	0%	51.9	1,557,738	Common Stock
Travere Therapeutics Inc	Jula Inrig	CHIEF MEDICAL OFFICER	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	30,000	89,443 (0%)	0%		0	Common Stock
Phreesia Inc	Evan Roberts	Chief Operating Officer		31 Jan 2025	30,000	0	-		-	Stock Option (Right to Buy)
Phreesia Inc	Evan Roberts	Chief Operating Officer		31 Jan 2025	30,000	794,307 (2%)	0%	0.8	25,200	Common Stock
BlackRock Enhanced Equity Dividend Trust Board Meeting	Antonio DeSpirito	Portfolio Manager	Sale or transfer of securities back to the company at price $ 8.79 per share.	31 Jan 2025	29,434	0 (0%)	0%	8.8	258,733	Common Stock
BlackRock Enhanced Equity Dividend Trust Board Meeting	Antonio DeSpirito	Portfolio Manager	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	29,434	29,434 (0%)	0%		-	Common Stock
Jackson Fin Inc (Class A)	Scott E. Romine	President and CEO, JNLD	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	29,362	92,276	-		0	Common Stock
Natera Inc	Matthew Rabinowitz	Director, EXECUTIVE CHAIRMAN	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	29,345	2,412,522 (3%)	0%		-	Common Stock
Nutriband Inc	Gareth Sheridan	Director, Chief Executive Officer, Ten Percent Owner		31 Jan 2025	29,333	251,000	-		-	Stock Option
Xeris Biopharma Holdings Inc	Kevin McCulloch	See Remarks	Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share.	31 Jan 2025	29,300	1,548,152 (5%)	0%	3.6	104,308	Common Stock
Cognition Therapeutics Inc	Lisa Ricciardi	Director, CEO & President	Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share.	31 Jan 2025	28,960	262,385	-	0.7	19,287	Common Stock
Urban Edge Properties	Mark J. Langer	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	28,677	28,677	-		-	LTIP Units (2025 LTI Time)
Clover Health Investments Corp (Class A)	Karen M. Soares	General Counsel & Secretary	Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.39 per share.	31 Jan 2025	28,553	1,357,508	-	4.4	125,348	Class A Common Stock
Zentalis Pharma Inc High Gain High Volume	Julie Eastland	Director, CEO & President	Purchase of securities on an exchange or from another person at price $ 1.73 per share.	31 Jan 2025	28,500	28,500	-	1.7	49,345	Common Stock
Deluxe Corp	Barry C. McCarthy	Director, President & CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.42 per share.	31 Jan 2025	28,426	209,877 (0%)	0%	23.4	665,737	Common Stock
Ally Fin Inc Results Board Meeting	Douglas R. Timmerman	President, DFS	Grant, award, or other acquisition of securities at price $ 39.06 per share.	31 Jan 2025	28,418	536,156 (0%)	0%	39.1	1,110,007	Common Stock
Cohen & Steers Inc	Jon Cheigh	President and CIO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	27,973	167,134 (0%)	0%		0	Common Stock
Lightpath Tech Inc (Class A)	Shmuel Rubin	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	27,697	225,722 (0%)	0%		-	Class A common stock
Ramaco Resources Inc (Class A)	John C. Marcum	EVP for Production	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	27,506	151,074	-		0	Class A common stock
Corbus Pharma Holdings Inc	Sean F. Moran	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	27,500	76,105 (0%)	0%		0	Common Stock, par value $0.0001 per share
BlackRock Innovation & Growth Trust	Philip Ruvinsky	Portfolio Manager	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	27,424	0	-		-	Phantom Shares
Akebia Therapeutics Inc	Steven Keith Burke	SVP, Chief Medical Officer	Sale of securities on an exchange or to another person at price $ 2.10 per share.	31 Jan 2025	27,236	816,234 (0%)	0%	2.1	57,196	Common Stock
Corbus Pharma Holdings Inc	Dominic Smethurst	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	27,200	77,200 (0%)	0%		0	Common Stock, par value $0.0001 per share
Immersion Corp Dividend	William C. Martin	Director, Chief Strategy Officer	Purchase of securities on an exchange or from another person at price $ 7.55 per share.	31 Jan 2025	27,150	1,450,693 (4%)	0%	7.6	204,983	Common Stock
Manhattan Associates Inc Results Board Meeting	Eddie Capel	Director, President & CEO	Payment of exercise price or tax liability using portion of securities received from the company at price $ 208.59 per share.	31 Jan 2025	27,099	203,315 (0%)	0%	208.6	5,652,580	Common Stock
BioXcel Therapeutics Inc	David J. Mack	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	27,089	81,267 (0%)	0%		-	Common Stock
BioXcel Therapeutics Inc	David J. Mack	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	27,089	243,810	-		-	Restricted Stock Units
Xcel Brands Inc	Seth Burroughs	EVP of BD Treasurer Secretary	Grant, award, or other acquisition of securities at price $ 0.42 per share.	31 Jan 2025	26,830	445,047 (2%)	0%	0.4	11,349	Common Stock
EVgo Inc (Class A)	Dennis G. Kish	President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	26,818	0	-		-	Restricted Stock Units
EVgo Inc (Class A)	Dennis G. Kish	President	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	26,818	88,087	-		-	Class A Common Stock
Surgery Partners Inc	David T. Doherty	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	26,784	122,503 (0%)	0%		0	Common Stock
Teradyne	Gregory Stephen Smith	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	26,773	101,528 (0%)	0%		0	Common Stock
Plexus Corp Results	Todd P. Kelsey	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	26,770	0	-		-	Restricted Stock Units
Plexus Corp Results	Todd P. Kelsey	Director, President & CEO	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	31 Jan 2025	26,770	101,041 (0%)	0%		-	Common Stock, $.01 par value
NextDecade Corp	William Vrattos	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	26,533	26,533 (0%)	0%		0	Common Stock
NextDecade Corp	Brian Belke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2025	26,533	391,770 (0%)	0%		0	Common Stock

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.

Insider trading for US stocks based on disclosures made made on Jan 31, 2025

Monitor US insider transactions and discover insider buying and selling of stocks on Jan 31, 2025.

The latest disclosure under SEC insider trading regulations was reported by XBiotech Inc., where the revocation of 2,470,355 Convertible Loan Agreement of common stock was executed . This transaction was reported to the Securities and Exchange Commission on Jan. 31, 2025.

Screeners based on Insider Trading parameters